TABLE 4.

Overview of phenotypically susceptible isolates with high (Hi), moderate (Mo) or minimal (Mi) confidence corrected interpretative best confidence values (iBCVs)

Drug	Drug-resistant phenotype	Hi confidence iBCVs			Hi+Mo confidence iBCVs			Hi+Mo+Mi confidence iBCVs
		False-susceptible	Resistance missed % (95% CI)	Difference in sensitivity %	False-susceptible	Resistance missed % (95% CI)	Difference in sensitivity %	False-susceptible	Resistance missed % (95% CI)	Difference in sensitivity %
Rifampicin (R)	8294	55	0.7 (0.5–0.9)	0.1	124	1.5 (1.2–1.8)	0.2	192	2.3 (2.0–2.6)	0.2
Isoniazid (H)	11001	55	0.5 (0.4–0.7)	0.2	81	0.7 (0.6–0.9)	0.2	81	0.7 (0.6–0.9)	0.2
Moxifloxacin (MFX)	517	50	8.8 (6.6–11.5)	1.0	50	8.8 (6.6–11.5)	1.0	50	8.8 (6.6–11.5)	1.0
Ofloxacin (OFX) /levofloxacin (LFX)	3809	93	2.4 (1.9–2.9)	0.5	94	2.4 (2.0–2.9)	0.5	94	2.4 (2.0–3.0)	0.5
Amikacin (AM)	809	6	0.7 (0.3–1.6)	0.2	6	0.7 (0.3–1.6)	0.2	6	0.7 (0.3–1.6)	0.2
Kanamycin (KM)	943	25	2.6 (1.7–3.8)	0.8	25	2.6 (1.7–3.8)	0.8	25	2.6 (1.7–3.8)	0.8
Capreomycin (CM)	810	109	11.9 (9.8–14.1)	3.9	109	11.9 (9.8–14.1)	3.9	109	11.9 (9.8–14.1)	3.9
Streptomycin (S)	2204	16	0.7 (0.4–1.2)	0.3	16	0.7 (0.4–1.2)	0.3	16	0.7 (0.4–1.2)	0.3
Ethionamide and prothionamide (ETO/PTO)	298	0	0.0 (0.0–1.2)	0.0	7	2.3 (0.9–4.7)	1.2	7	2.3 (0.9–4.7)	1.2
Pyrazinamide (Z)	2595	59	2.2 (1.7–2.9)	0.8	67	2.5 (2.0–3.2)	0.9	83	3.1 (2.5–3.8)	1.0

The resistance missed corresponds to the false-susceptible isolates divided by the “corrected phenotype”, consisting of the sum of phenotypically resistant isolates and false-susceptible isolates (the probable smallest and largest figures in each category are shown in bold). The difference in sensitivity was calculated by subtracting the sensitivity for the “observed phenotype” from the sensitivity of the “corrected phenotype” (both sensitivities are plotted in figure 2a).